Abstract
This meta-analysis examines the impacts of the COVID-19 pandemic on mental health in Latin America during its first year, using data from 71 studies with 231,441 participants. To address knowledge gaps in the existent literature we considered the type of study design, country of origin, effects of lockdown, and several potential moderating factors. We found prevalence rates of 31% for depression symptoms and 36% for anxiety symptoms. These estimates were higher than those observed in studies from the northern hemisphere. Longitudinal studies showed that depressive symptoms persisted over time, and lockdowns were associated with mildly increased anxiety levels. Female gender was associated with higher rates of depressive symptoms. Our analyses revealed high statistical heterogeneity, and moderating factors such as pandemic duration, COVID-19 cases and deaths, and lockdown stringency did not explain observed mental health symptoms. Methodological limitations include an overreliance on cross-sectional studies and a lack of pre-pandemic parameters that may lead to an overestimation of mental health symptom rates. Overall, this study provides valuable insights into mental health symptoms in Latin America during the first year of the COVID-19 pandemic, highlighting the need for improved epidemiological research and mental health support in the region.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Interamerican Development Bank (RG-T3106) and INECO Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript and in the Supplementary material
